Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Road To Restoring Credibility: How Maintaining A Good Reputation With FDA Can Be An Uphill Battle For Manufacturers – But It's Possible

This article was originally published in The Gray Sheet

Executive Summary

From our digital archives: Manufacturers can develop a bad reputation with FDA for a variety of reasons, including failing to systemically fix problems or follow through on commitments. “It’s tiresome, frankly, as a regulator, to have firms come in and pay lip service to the steps that they’re going to take, and then not follow up to demonstrate that they’ve taken those steps,” former CDRH Office of Compliance Director Steven Silverman said in December 2011. Two former agency officials also pointed out why FDA doesn’t trust some companies. Plus: A former Gambro Renal Products official explained how that firm's staff worked to change FDA’s perception of the company after it imposed an import ban on the firm in 2006.

You may also be interested in...



Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Scrip’s Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.

Topics

Related Companies

UsernamePublicRestriction

Register

MT034616

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel